CSL Behring announced a multi-year, $450 million two-site global capacity expansion. This expansion strengthens CSL Behring’s global manufacturing capabilities with production capacity increases of albumin at its Broadmeadows facility in Melbourne, Australia and plasma intermediates at its Kankakee site in Illinois, U.S. The company says the cross-functionality that is enabled by the capacity expansions will allow it to leverage its global manufacturing network, helping to optimize the manufactu...